ABL Bio to Present Clinical Data for Two "Grabody-T" Bispecific Antibodies at ESMO 2026
Givastomig Phase 1b Expansion Data
Ragistomig Dose-Optimization Results to Be Presented
ABL Bio will present clinical results for two 4-1BB-based bispecific immuno-oncology drugs at Europe's largest oncology conference.
On Oct. 19, ABL Bio (CEO Lee Sang-hoon) said it will present clinical data for givastomig (ABL111) and ragistomig (ABL503) in poster presentations at the European Society for Medical Oncology Congress (ESMO 2026), to be held in Madrid, Spain, from Oct. 23 to 27 (local time).
Both candidates are part of a pipeline using Grabody-T, ABL Bio's proprietary 4-1BB-based bispecific antibody platform. Givastomig targets Claudin 18.2, which is overexpressed in cancers including gastric and pancreatic cancer, while ragistomig targets the immune checkpoint protein PD-L1. Both drugs are being jointly developed with U.S. biotechnology company Novabridge Biosciences.
Givastomig is currently in a Phase 2 clinical trial in combination with the PD-1 inhibitor nivolumab and chemotherapy. At the conference, ABL Bio will present updated data on the safety and efficacy of the combination therapy observed in a Phase 1b trial. Givastomig has received Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration (FDA).
ABL Bio has expanded the ongoing Phase 1 trial of ragistomig by adding a monotherapy cohort for new cancer types, and has also begun evaluating its combination with a PD-1 inhibitor. At ESMO, the company plans to present Phase 1 monotherapy dose-optimization data under the title "Dose Optimization of Ragistomig, a PD-L1 x 4-1BB Bispecific Antibody."
Hot Picks Today
"300,000 Won Grant" Shelved at Chuseok to Go to All Residents After All... This City Says It Will Pay Before Lunar New Year
- "Didn't Save This Money to Leave to Our Kids?"... Retired Couples Spend $10,000 on a Single Trip
- "Make $10 Million by Flipping It Right After Delivery?"... The Market Drawing the World's Ultra-Rich in ‘This Market’
- Friend Who Went Abroad Goes "Silent"... 617 South Koreans Out of Contact, What's Going On?
- "Stockpile 9 Liters of Bottled Water and Three Days' Worth of Food"... UK on Edge as Nationwide Emergency Preparedness Alert Issued
ABL Bio is developing various nonclinical and clinical pipelines based on platforms including Grabody-B, a blood-brain barrier (BBB) shuttle platform, and Grabody-T. In addition to ABL111 and ABL503, ABL103, ABL105, ABL104, ABL206 and ABL209 are undergoing clinical trials in the United States, China, Australia, Japan and South Korea.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
